✦ LIBER ✦

Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy

✍ Scribed by Rita de Cássia RosáRio Cavalheiro; Perla Vicari; Fernanda Maria Morselli; Larissa Veloso M Ommati; Fanny de Oliveira Frazão Rosa; José Salvador Rodrigues Oliveira

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 237 KB
Volume: 81
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20451

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Unusual extramedullary relapses under im

Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia

✍ Yavuz Beyazit; Salih Aksu; Murat Kekilli; Ibrahim C. Haznedaroglu; Sadettin Kili 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

Imatinib mesylate-sensitive blast crisis

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases

✍ Takehiro Higashi; Junichi Tsukada; Chiaki Kato; Atsushi Iwashige; Takamitsu Mizo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 1 views

Successful treatment of chronic myeloid

Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis

✍ Evren Ozdemir; Yener Koc; Emin Kansu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 1 views

Imatinib mesylate induces hypophosphatem

Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response

✍ S. Osorio; A. García Noblejas; A. Durán; J.L. Steegmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

Brain natriuretic peptide level as marke

Brain natriuretic peptide level as marker of cardiac function in imatinib—Treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy

✍ Mario Tiribelli; Antonio Colatutto; Luciana Marin; Giuseppe Barbina; Ugo Qualizz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

Inv (11)(p15q21) in donor-derived Ph-neg

Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation

✍ Bruno C. Medeiros; Kathy Chun; Suzanne Kamel-Reid; Jeffrey Lipton 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract Imatinib mesylate (IM) is the standard first‐line treatment for patients with chronic myeloid leukemia (CML). Surprisingly, 2–15% of patients achieving a complete cytogenetic response develop cytogenetic abnormalities in Philadelphia (Ph)‐negative cells. Following hematopoietic stem cel